Targeting IL-6/STAT3 signaling abrogates EGFR-TKI resistance through inhibiting Beclin-1 dependent autophagy in HNSCC

Area of Science:

• Oncology
• Molecular Biology
• Cancer Signaling Pathways

Background:

• Head and neck squamous cell carcinoma (HNSCC) often develops resistance to EGFR tyrosine kinase inhibitors (TKIs) due to parallel pathway activation.
• Clinical trials show limited success with EGFR-TKIs in advanced HNSCC, highlighting the need for alternative strategies.
• The role of the IL-6/STAT3 signaling axis in EGFR-TKI resistance in HNSCC remains unclear.

Purpose of the Study:

• To investigate the role of STAT3 signaling in EGFR-TKI resistance in HNSCC.
• To evaluate the efficacy of targeting STAT3 in combination with EGFR-TKIs for HNSCC treatment.
• To elucidate the mechanisms by which STAT3 confers resistance and how its blockade impacts tumor apoptosis and autophagy.

Main Methods:

• In vitro and in vivo experiments using HNSCC cell lines and animal models.
• Exposure of HNSCC cells to EGFR-TKIs to assess STAT3 signaling activation.
• Combination therapy studies involving EGFR-TKIs and small molecule STAT3 inhibitors.
• Analysis of STAT3 phosphorylation, autophagic flux, and tumor apoptosis.

Main Results:

• STAT3 signaling is upregulated in response to EGFR-TKI treatment in HNSCC, conferring resistance.
• Combined inhibition of STAT3 and EGFR-TKIs resulted in complete tumor elimination in vitro and in vivo.
• STAT3 activation enhances oncogenic autophagy, protecting HNSCC cells from apoptosis induced by EGFR-TKIs.

Conclusions:

• STAT3 signaling is a key mediator of EGFR-TKI resistance in HNSCC.
• Combined targeting of STAT3 and EGFR-TKIs represents a promising therapeutic strategy for advanced HNSCC.
• STAT3 may serve as a predictive biomarker for response to EGFR-TKI therapy in HNSCC patients.